acetylphenylalanyl-prolyl-boroarginine has been researched along with arginine in 7 studies
Studies (acetylphenylalanyl-prolyl-boroarginine) | Trials (acetylphenylalanyl-prolyl-boroarginine) | Recent Studies (post-2010) (acetylphenylalanyl-prolyl-boroarginine) | Studies (arginine) | Trials (arginine) | Recent Studies (post-2010) (arginine) |
---|---|---|---|---|---|
30 | 0 | 0 | 46,388 | 1,688 | 11,176 |
Protein | Taxonomy | acetylphenylalanyl-prolyl-boroarginine (IC50) | arginine (IC50) |
---|---|---|---|
Cationic amino acid transporter 3 | Homo sapiens (human) | 283 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (71.43) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Callas, DD; Fareed, J | 2 |
Boudon, A; De Nanteuil, G; Gloanec, P; Lila, C; Portevin, B; Rupin, A; Verbeuren, TJ | 1 |
Gustafsson, D; Lenfors, S | 1 |
Verstraete, M | 1 |
Harding, SR; Lyon, AW; Lyon, ME; Oosman, SN | 1 |
Chesebro, JH; Grill, DE; Hassinger, NL; McBane, RD; Mruk, JS | 1 |
1 review(s) available for acetylphenylalanyl-prolyl-boroarginine and arginine
Article | Year |
---|---|
Modulating platelet function with selective thrombin inhibitors.
Topics: Administration, Oral; Adult; Animals; Antithrombins; Arginine; Blood Platelets; Boron Compounds; Clinical Trials as Topic; Dogs; Drug Evaluation, Preclinical; Glycine; Hirudin Therapy; Hirudins; Humans; Naphthalenes; Oligopeptides; Peptide Fragments; Pipecolic Acids; Piperidines; Recombinant Proteins; Sulfonamides; Thrombin | 1996 |
6 other study(ies) available for acetylphenylalanyl-prolyl-boroarginine and arginine
Article | Year |
---|---|
Direct inhibition of protein Ca by site directed thrombin inhibitors: implications in anticoagulant and thrombolytic therapy.
Topics: Antifibrinolytic Agents; Antithrombin III; Antithrombins; Aprotinin; Arginine; Binding Sites; Boron Compounds; Enzyme Activation; Fibrinolysis; Heparin; Hirudins; Humans; Oligopeptides; Peptide Fragments; Pipecolic Acids; Protein C; Recombinant Proteins; Sulfonamides; Thrombin | 1995 |
New tripeptidic thrombin inhibitors. Influence of P2 and P3 residues on activity and selectivity.
Topics: Amino Acid Sequence; Antithrombins; Arginine; Binding Sites; Boron Compounds; Fibrinolysin; Molecular Sequence Data; Molecular Structure; Oligopeptides; Structure-Activity Relationship; Thrombin | 1995 |
Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method.
Topics: Antithrombins; Arginine; Blood Coagulation Tests; Boron Compounds; Dose-Response Relationship, Drug; Endopeptidases; Enzyme Precursors; Fibrinolytic Agents; Heparin; Hirudins; Humans; Oligopeptides; Partial Thromboplastin Time; Pipecolic Acids; Prothrombin; Sulfonamides; Thrombin | 1996 |
New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors.
Topics: Animals; Antithrombins; Arginine; Batroxobin; Boron Compounds; Disease Models, Animal; Dose-Response Relationship, Drug; Fibrinolysis; Injections, Intravenous; Male; Oligopeptides; Pipecolic Acids; Rats; Rats, Sprague-Dawley; Sulfonamides; Thrombin | 1996 |
Evaluation of argatroban and DUP 714 as anticoagulants for blood gas, electrolyte and ionized calcium analyses.
Topics: Antithrombins; Arginine; Blood Gas Analysis; Boron Compounds; Calcium; Chemistry, Clinical; Electrolytes; Evaluation Studies as Topic; Humans; Hydrogen-Ion Concentration; Oligopeptides; Oximetry; Pipecolic Acids; Sulfonamides | 2000 |
Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin.
Topics: Angioplasty, Balloon; Animals; Anticoagulants; Arginine; Boron Compounds; Drug Evaluation, Preclinical; Hirudins; Oligopeptides; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Swine; Thrombin; Thrombosis | 2005 |